Placeholder

InVivoPlus anti-mouse OX40 (CD134)

$ 390.00$ 4,000.00

SKU: BP0031 Categories: ,

be0031-ox-86

Clear
Quotes for sizes >100 mg
References SDS Sheet

 

InVivoPlus anti-mouse OX40 (CD134)

Clone: OX-86 Catalog#: BP0031

Storage:Undiluted at 4C in the dark.
Production:Tissue culture
Isotype:Rat IgG1
Purification:Protein G
Recommended Dilution Buffer:InVivoPure pH 7.0 Dilution Buffer
Recommended Isotype Control:HRPN
Reported Applications:in vivo OX40 activation
in vitro OX40 activation
Western blot
Endotoxin: <1EU/mg (<0.001EU/μg)

Endotoxin level is determined using an LAL gel clotting test.
Aggregation: <5%Aggregation determined by DLS
Purity: > 95%Purity determined by SDS-PAGE.
Formulation: PBS, pH 7
Sterile: 0.2 µm filtration
Murine Pathogen Test Results: Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Minute Virus: Negative
Mouse Hepatitis Virus: Negative
Reovirus Screen: Negative
Lymphocytic Choriomeningitis virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Mouse Rotavirus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
Polyoma Virus: Negative
Mouse Adenovirus: Negative
Sendai Virus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Mouse Cytomegalovirus: Negative
K Virus: Negative

Description:

The OX-86 monoclonal antibody reacts with mouse OX-40 also known as CD134. OX-40 is a 50 kDa type I membrane glycoprotein and a member of the TNF receptor superfamily. OX-40 is expressed on activated CD4 and CD8 T cells, but is not found on resting naïve T cells or most resting memory T cells. Although it was originally thought that OX-40 expression was restricted to activated conventional T cells, it has now been visualized on activated regulatory T cells, NKT cells, NK cells, and neutrophils. OX-40 plays a major role in regulating both CD4 and CD8 T cell clonal expansion. It provides a costimulatory signal to an antigen-reacting naive T cells to prolong proliferation, as well as augment the production of several cytokines. This is demonstrated by OX-40 knockout mice which generate fewer primary effector CD4 T cells after immunization. Furthermore, in vivo treatment with an agonist antibody to OX-40 has been shown to strongly enhance the generation of antigen-specific effector T cells and prevent the induction of T cell tolerance. The OX-86 antibody is an agonistic antibody that has been shown to delay tumor growth in vivo.